TrialPath

4 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Obesity / overweightFatty liver disease (NASH/MASH)

    📍 Banner Health Center · Phoenix, AZ · +3 more US sites · Get directions →

    Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma.

    ✓ Study care freePhase 4Ages 18–75Learn more →
  • Type 2 diabetesFatty liver disease (NASH/MASH)

    📍 Texas Diabetes Institute - University Health System · San Antonio, TX · +1 more US site · Get directions →

    In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Obesity / overweightHeart / cardiovascular diseaseHigh cholesterol

    📍 London Health Sciences Centre - Victoria Hospital · London, Ontario · Get directions →

    The overriding objectives of this study are: 1. Primary outcomes: 1.

    ✓ Study care freeEarly Phase 1Ages 18+MenLearn more →
  • Obesity / overweightHigh cholesterol

    📍 University of Connecticut · Storrs, CT · Get directions →

    The major objective of this project is to examine whether daily consumption of milk polar lipids (MPLs) influences cardiometabolic risk factors.

    ✓ Study care freeEarly Phase 1Ages 18–70Learn more →